Pyxis Oncology Q3 EPS $(0.85) Up From $(8.96) YoY

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.

byBenzinga Newsdesk

November 1, 2022

1 minute read

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.

Powerbridge Technologies Establishes Cryptocurrency Mining Fleets For Bitcoin And Ethereum In Hong Kong

By Benzinga Newsdesk

Today, 11:15 PM

Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) ("Powerbridge" or the "Company"), a SaaS solutions and Blockchain applications provider, is proud to announce that Powercrypto Holdings

PBTS

Earnings

Cyclo Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 11:15 PM

According to data from Benzinga Pro, during Q4, Cyclo Therapeutics's (NASDAQ:CYTH) reported sales totaled $585.12 thousand. Despite a 27.66% increase in earnings, the company posted a loss of $2.79 million.

CYTH

Jefferies Says Bed Bath & Beyond Bankruptcy Risk Is Priced In, Given BBBY’s <$350M Market Cap And High Short Interest, We Believe The Potential To Capture An Incremental ~$800M In Gross Proceeds From The Equity Deal Could Lead To A Spike In Shares..

By Happy Mohamed

Today, 11:15 PM

Bed Bath & Beyond Bankruptcy Risk Is Priced In, Jefferies Says. Given BBBY's <$350M market cap and high short interest, we believe the potential to capture an incremental ~$800M in gross proceeds from the

BBBY